MedTrace Logo

A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours

NCT01396408 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 137

Last updated 2026-03-27

No results posted yet for this study

Summary

This research is being done because there is no treatment that will cure this type of cancer. Although some types of chemotherapy can cause this cancer to shrink for a time, better options are needed.

Conditions

  • Advanced Rare Tumours

Interventions

DRUG

Sunitinib

50 mg PO daily for 28 days, q 6 weeks (1 cycle=6 weeks or 42 days)

DRUG

Temsirolimus

25 mg IV weekly (Days 1, 8, 15, 22, 29, 36), q 6 weeks (1 cycle=6 weeks or 42 days)

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Hal Hirte · Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON Canada

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-09
Primary Completion
2015-07-06
Completion
2026-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01396408 on ClinicalTrials.gov